| About the author: |
G. S. Maslova, R. І. Skrypnyk, I. N. Skrypnyk |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The paper presents the findings of our studies on the assessment of the effectiveness of L-ornithine-L-aspartate in the prophylactic of chemotherapy-induced liver injury in patients with multiple myeloma. 24 patients with multiple myeloma were examined (11 females and 13 males, ages 46–78). The condition assessment was conducted twice: before chemotherapy and after 3 courses of chemotherapy. Patients were analyzed for the following biochemical parameters: the activity of alanine and asparagine aminotransferases, gamma-glutamyltranspeptidase, alkaline phosphatase, total bilirubin, total protein, creatinine, urea, total blood calcium level. Depending on the inclusion of L-ornithine-L-aspartate as an adjuvant treatment, patients were divided into 2 groups: group I (n=12) – patients with multiple myeloma, who underwent only chemotherapy; group II (n=12) – patients with multiple myeloma, who during chemotherapy received L-ornithine-L-aspartate at a dose of 10 g/day intravenously for 10 days, then 5 g 2 twice a day for 20 days. Group ІІІ (n=20) the control group, included 20 practically healthy persons. It was established, that application of L-ornithine-L-aspartate as an adjuvant treatment in patients with multiple myeloma that undergo chemotherapy provides the effective prophylactic of pathological alterations in liver and kidney functional state. |
| Tags |
chemotherapy, hepatotoxicity, nephrotoxicity, adjuvant therapy |
| Bibliography |
- Nakaz MOZ Ukrayiny` vid 30.07.2010 No. 647 “Pro zatverdzhennya klinichnykh protokoliv nadannya medychnoyi dopomogy khvorym zi spetsialnosti “Gematologiya” [in Ukrainian]
- Skrypnyk IM, Maslova HS, SkrypnykRI. Vplyv L-ornitynu-L-aspartatu na vyiavy minimalnoyi pechinkovoyi entsefalopatiyi v dynamitsi tsytostatychnoyi terapiyi. Suchasna hastroenterolohiya. 2018;6(104):29–34. [in Ukrainian]
- Coffey D, Fain B, Thompson C, Chan ED, Nawaz S. Liver failure as the only clinical manifestation of multiple myeloma. Ann Hematol. 2012;91(4):625–7. doi: 10.1007/s00277-011-1284-2
- Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA Oncol [Internet]. 2018; Available from: http://dx.doi.org/10.1001/jamaoncol.2018.2128
- Cull S, Westrich DJ Jr, Bhatia R, Lai J, BefelerAS. Multiple myeloma presenting as acute liver failure. ACG Case Rep J. 2017;4(1):e85. doi: 10.14309/crj.2017.85
- Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28: 52–61. doi: 10.1093/annonc/mdx096
- Murakami J, Shimizu Y. Hepatic manifestations in hematological disorders. Int J Hepatol. 2013;2013:484903. doi:10.1155/2013/484903
- Perez-Soler R, Esteban R, Allende E, Tornos Salomo C, Julia A, Guardia J. Liver involvement in multiple myeloma. Am J Hematol. 1985;20(1):25–9.
- Ricart AD. Drug-induced liver injury in Oncology. Ann Oncol. 2017;28(8):2013–20. doi: 10.1093/annonc/mdx158
- Stansfield LC, GonsalvesWI, Buadi FK. The use of novel agents in multiple myeloma patients with hepatic impairment. Future Oncol. 2015;11(3):501–10. doi:10.2217/fon.14.270
- Thomas FB, Clausen KP, Greenberger NJ. Liver disease in multiple myeloma. Arch Intern Med. 1973;132(2):195–202.
- Yadav P, Cook M, Cockwell P. Current Trends of Renal Impairment in Multiple Myeloma. Kidney Dis 2015;1:241–257. doi: 10.1159/000442511
|
| Publication of the article |
«World of Medicine and Biology» №4(78), 2021 year, 100-104 pages, index UDK 616.36-006-085 |
| DOI |
10.26724/2079-8334-2021-4-78-100-104 |
